ATE491465T1 - Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen - Google Patents

Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen

Info

Publication number
ATE491465T1
ATE491465T1 AT05076809T AT05076809T ATE491465T1 AT E491465 T1 ATE491465 T1 AT E491465T1 AT 05076809 T AT05076809 T AT 05076809T AT 05076809 T AT05076809 T AT 05076809T AT E491465 T1 ATE491465 T1 AT E491465T1
Authority
AT
Austria
Prior art keywords
antigen
cells
activated
pbls
loaded
Prior art date
Application number
AT05076809T
Other languages
English (en)
Inventor
Babita Agrawal
Mark J Krantz
Mark A Reddish
Michael B Longenecker
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Application granted granted Critical
Publication of ATE491465T1 publication Critical patent/ATE491465T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05076809T 1997-05-08 1998-05-07 Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen ATE491465T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08

Publications (1)

Publication Number Publication Date
ATE491465T1 true ATE491465T1 (de) 2011-01-15

Family

ID=21940709

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98921011T ATE394474T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
AT05076809T ATE491465T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98921011T ATE394474T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Country Status (10)

Country Link
US (1) US6600012B1 (de)
EP (3) EP0986636B1 (de)
JP (1) JP4480800B2 (de)
AT (2) ATE394474T1 (de)
AU (1) AU727863B2 (de)
CA (1) CA2289742C (de)
DE (2) DE69839443D1 (de)
DK (1) DK1634949T3 (de)
ES (1) ES2357960T3 (de)
WO (1) WO1998050527A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
GB9921337D0 (en) 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
EP1572918B1 (de) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetische glykolipopeptide als impfstoffe
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
CA2501527A1 (en) * 2002-10-10 2004-04-22 Catherine A. Phillips Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
JP5060134B2 (ja) * 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1812052A1 (de) * 2004-11-02 2007-08-01 Biomedical Research Models, Inc. Verfahren zur krebsbehandlung/-prävention unter verwendung krebszellenspezifischer oberflächenantigene
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2377994C1 (ru) * 2008-05-21 2010-01-10 Леонид Валентинович Загребин Способ иммунореабилитации онкозаболеваний
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
RU2578420C2 (ru) 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
WO2013103658A1 (en) 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
JP2016520073A (ja) 2013-05-14 2016-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｍｕｃ−１リポペプチドによるワクチン免疫で肺癌を治療する方法
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2135068T3 (es) 1994-06-13 1999-10-16 Unilever Nv Activacion de blanqueantes.
DK0765386T3 (en) * 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
AU6330896A (en) * 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Also Published As

Publication number Publication date
US6600012B1 (en) 2003-07-29
EP1634949B1 (de) 2010-12-15
CA2289742C (en) 2013-07-16
JP2001525668A (ja) 2001-12-11
JP4480800B2 (ja) 2010-06-16
EP0986636B1 (de) 2008-05-07
ATE394474T1 (de) 2008-05-15
AU7371298A (en) 1998-11-27
EP1634949A1 (de) 2006-03-15
DE69842060D1 (de) 2011-01-27
ES2357960T3 (es) 2011-05-04
WO1998050527A1 (en) 1998-11-12
EP2341072A2 (de) 2011-07-06
CA2289742A1 (en) 1998-11-12
EP2341072A3 (de) 2013-10-30
AU727863B2 (en) 2001-01-04
DK1634949T3 (da) 2011-03-28
DE69839443D1 (de) 2008-06-19
EP0986636A1 (de) 2000-03-22

Similar Documents

Publication Publication Date Title
ATE394474T1 (de) Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
ATE325802T1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
ATE116329T1 (de) Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
IL219223B (en) Non-naturally occurring antigen-presenting cells (nnapc) derived from drosophila melanogaster cells for use in preparing a suspension of cd8+ cells and methods for their manufacture
IL152472A0 (en) Methods of producing membrane vesicles
PT2092938E (pt) Péptidos derivados de survivina e a sua utilização
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
CY1106400T1 (el) Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
ES2167561T3 (es) Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.
ES2190432T3 (es) Activacion in vitro de celulas t citotoxicas.
ES2059537T3 (es) Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.
EP1470821A3 (de) Zelltherapieverfahren zur Behandlung von Tumoren
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
PL364747A1 (en) Use of antibodies for anticancer vaccination
Slovin et al. Immunological approaches for the treatment of prostate cancer
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
ATE276364T1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
WO2000015767A3 (en) Antigen-presenting cells and their use in therapy

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1634949

Country of ref document: EP